Diagnosed prevalent cases of Parkinson’s disease will grow at 1.94% annually in the seven major markets between 2023 and 2033 ...

The Phase III BROOKLYN trial saw HeFH patients randomly assigned in a 2:1 ratio to receive either obicetrapib or a placebo ...

The UK’s NICE has rejected a deal for the reimbursement of Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu for ...

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.

UK Health Secretary Wes Streeting outlaid the key shifts needed to fix a “fragmented” NHS at the Jefferies London Healthcare ...

The US FDA has issued a CRL for sNDA of Astellas Pharma’s IZERVAY, a treatment for geographic atrophy (GA) secondary to AMD.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

The upcoming clinical trial conferences will host talks on supply chain resilience, AI’s growing role and forging industry ...

ReCode is set to secure up to $15m in funding from the Cystic Fibrosis Foundation to enhance its gene correction research ...

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.